前列地尔与胰激肽原酶联合治疗糖尿病肾病的疗效  

Curative Effect of Alprostadil Combined with Kallidinogenase on Diabetic Nephropathy

作　　者：张祥林[1] 王春梅[1] 杜鹃[1] 徐怡[1] 

机构地区：[1]上海市复旦大学附属华山医院宝山分院内分泌科,上海200431

出　　处：《中国生物制品学杂志》2008年第10期896-898,共3页Chinese Journal of Biologicals

摘　　要：目的观察前列地尔与胰激肽原酶联合治疗糖尿病肾病(DN)的疗效。方法将81名DN患者随机分为联合用药组(前列地尔+胰激肽原酶)和对照组(胰激肽原酶)。比较两组治疗前、后尿微量白蛋白(MAU)、24h尿蛋白定量(24-UP)、血尿素氮(BUN)、血肌酐(Scr)、肌酐清除率(Ccr)、全血黏度、血浆黏度及纤维蛋白原含量的变化。结果两组治疗2个月后,MAU、24-UP、BUN、Scr、全血黏度、血浆黏度及纤维蛋白原含量均下降,Ccr均升高,联合用药组治疗后差异更为显著。结论前列地尔与胰激肽原酶联合治疗DN较单独口服胰激肽原酶疗效更理想。Objective To observe the curative effect of alprostadil combined with kallidinogenase on diabetic nephropathy （DN）. Methods Divide 81 patients with DN into 2 groups and treat by alprostadil combined with kallidinogenase and kallidinogenase alone respectively. Compare the MAU, 24-UP, BUN, SCr, Ccr, blood viscosity and fibrinogen content of the 2 groups before and after treatment. Results Both the Ccr of 2 groups 2 months after treatment increased, while other indexes decreased. However, the difference between above-mentioned indexes before and after treatment in the patients treated by alprostadil combined with kallidinogenase was more remarkable. Conclusion Compared with kallidinogenase alone, alprostadil combined with kallidinogenase showed more ideal curative effect on DN.

关 键 词：糖尿病肾病 前列地尔 胰激肽原酶 

分 类 号：R972.4[医药卫生—药品] R587.2[医药卫生—药学]